In 2021, Li et al. designed an EGFR CAR-T cell that incorporates a second receptor, CXCR5, with the aim of promoting the migration of CAR-T cells towards NSCLC tumors expressing CXCL13. Here, EGFR is linked to non-small cell lung carcinoma.